Paper Details

  1. Home
  2. Paper Details

A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.

Author: BlackfordAmanda L, BorrelloIvan, FergusonAnna, JonesRichard J, RobinsonTara M, SmithB Douglas, WarlickErica, WebsterJonathan A, ZahurakMarianna

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Adjuvant immunotherapy with TKIs could facilitate TKI discontinuation in CP-CML patients who achieve undetectable minimal residual disease. This suggests a potential strategy for improving long-term outcomes in CML.
Paper Details　
Original Abstract of the Article :
Chronic myeloid leukemia (CP-CML) patients can achieve undetectable minimal residual disease (UMRD) and discontinue tyrosine kinase inhibitors (TKIs). Cellular immunity plays an important role in CML disease control. We conducted a randomized, non-blinded phase II trial of adjuvant immunotherapy wit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/34768161

データ提供：米国国立医学図書館（NLM）

A New Oasis in Chronic Myeloid Leukemia (CML) Treatment

Chronic myeloid leukemia (CML) is a challenging blood cancer, and finding effective treatment options remains a priority. This study explores the potential of adjuvant immunotherapy, a promising approach that harnesses the power of the immune system to fight cancer, in patients with CML. The researchers conducted a randomized trial comparing the efficacy of adjuvant immunotherapy with tyrosine kinase inhibitors (TKIs) in patients with CML. The study suggests that adjuvant immunotherapy could facilitate TKI discontinuation, a major goal in CML management.

Immunotherapy: A New Hope for CML Treatment

This study offers promising evidence for the potential of adjuvant immunotherapy in CML treatment. The findings suggest that combining immunotherapy with TKIs could lead to a more durable response and potentially allow patients to discontinue TKIs.

Navigating the Desert of CML Treatment

This research highlights the evolving landscape of CML treatment, where innovative approaches like immunotherapy offer hope for patients. The study underscores the importance of exploring novel strategies to improve treatment outcomes and minimize side effects.

Dr. Camel's Conclusion

This study provides a glimpse into a potential oasis in the desert of CML treatment. Adjuvant immunotherapy, combined with TKIs, offers a promising avenue for enhancing treatment outcomes and potentially achieving long-term remission. The research continues to push the boundaries of CML treatment, opening new doors to a future where patients can lead healthier lives.

Date :
  1. Date Completed 2022-01-12
  2. Date Revised 2022-12-02
Further Info :

Pubmed ID

34768161

DOI: Digital Object Identifier

NIHMS1753303

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.